# A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors

> **NCT04623892** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** TQB2618 injection

## Key facts

- **NCT ID:** NCT04623892
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04623892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04623892, "A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04623892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*